Gilead REITERATED a Top Pick and 4 Stock Analyses Trending Now

Arctic Cat Inc. (NASDAQ:ACAT) price target was increased by Baird after its strong Q1 results. The firm cited the company’s robust revenue growth, strong product cycle, and less dealer restocking. The firm recommends buying on any dips in the share price, and it keeps its Outperform rating on the stock.

Meridian Bioscience Inc. (NASDAQ:VIVO) price target was reduced by Baird due to disappointing Q3 results. The firm blamed slowing growth in the diagnostic sector as well as stiff foreign exchange headwinds. Baird reiterates its Outperform rating but is not pounding the table.

Don’t Miss: Merck Earnings: Expands Margins AGAIN, TOPS Analyst Estimates.

Gilead Sciences Inc. (NASDAQ:GILD) price target was increased by JPMorgan, and the firm reiterated the stock as its top pick after the company’s Q2 results.

Amarin Corporation plc (NASDAQ:AMRN) price target was increased by Leerink after the FDA approved AMR101. Shares have an Outperform rating.

Crown Castle International Corp. (NYSE:CCI) target was raised by Stifel Nicolaus after the company delivered a beat and raise quarter. The firm believes that the company is in the position to benefit from positive industry trends, and it keeps a Buy rating on the stock.

Don’t Miss: Wall Street Brief: Facebook FALLS, Amazon LOSES, Starbucks MISSES.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.